tiprankstipranks
Advertisement
Advertisement

TAK Stock Latest News

Takeda Updates Articles of Incorporation in June 2026 SEC Filing
Company AnnouncementsTakeda Updates Articles of Incorporation in June 2026 SEC Filing
4d ago
6K
TAK
Takeda Shareholders Approve Dividend and Board Slate at 150th Annual Meeting
PremiumCompany Announcements
Takeda Shareholders Approve Dividend and Board Slate at 150th Annual Meeting
7d ago
6K
TAK
Takeda CEO Christophe Weber retires, Julie Kim succeeds
PremiumThe Fly
Takeda CEO Christophe Weber retires, Julie Kim succeeds
9d ago
TAK
Takeda Canada reports ‘positive’ results from Phase 3 study of zasocitinib
PremiumThe Fly
Takeda Canada reports ‘positive’ results from Phase 3 study of zasocitinib
9d ago
TAK
Takeda’s New Polish Study Tracks Real-World Impact of Fruquintinib in Advanced Colorectal Cancer
PremiumCompany Announcements
Takeda’s New Polish Study Tracks Real-World Impact of Fruquintinib in Advanced Colorectal Cancer
14d ago
TAK
Takeda’s High-Stakes Overhaul: CEO Transition and Major Restructuring Raise Execution and Profitability Risks
PremiumCompany AnnouncementsTakeda’s High-Stakes Overhaul: CEO Transition and Major Restructuring Raise Execution and Profitability Risks
15d ago
TAK
Takeda presents additional results from oveporexton studies at SLEEP 2026
Premium
The Fly
Takeda presents additional results from oveporexton studies at SLEEP 2026
17d ago
TAK
Takeda announces results for Phase 3 study of TAK-279
Premium
The Fly
Takeda announces results for Phase 3 study of TAK-279
21d ago
TAK
FDA accepts Takeda’s application for intravenous Entyvio
PremiumThe Fly
FDA accepts Takeda’s application for intravenous Entyvio
23d ago
TAK
Takeda’s TAK-360 Narcolepsy Trial Moves Forward, Expanding Its Specialty CNS Pipeline
PremiumCompany Announcements
Takeda’s TAK-360 Narcolepsy Trial Moves Forward, Expanding Its Specialty CNS Pipeline
23d ago
TAK
Takeda’s New Mezagitamab Trial Targets High-Risk Kidney Rejection, Bolstering Long-Term Pipeline Story
PremiumCompany Announcements
Takeda’s New Mezagitamab Trial Targets High-Risk Kidney Rejection, Bolstering Long-Term Pipeline Story
28d ago
TAK
Takeda’s Real-World Maribavir Study in Argentina: What Investors Should Watch
PremiumCompany Announcements
Takeda’s Real-World Maribavir Study in Argentina: What Investors Should Watch
28d ago
TAK
Innovent Biologics announces results from PoC study of IBI363
PremiumThe FlyInnovent Biologics announces results from PoC study of IBI363
1M ago
TAK
Takeda to Revise FY2025 IFRS Earnings Report After U.S. AMITIZA Antitrust Verdict
Premium
Company Announcements
Takeda to Revise FY2025 IFRS Earnings Report After U.S. AMITIZA Antitrust Verdict
1M ago
6K
TAK
Takeda Links Executive Pay to R&D Progress and TSR as FY2025 Results Reset Growth Path
Premium
Company Announcements
Takeda Links Executive Pay to R&D Progress and TSR as FY2025 Results Reset Growth Path
1M ago
6K
TAK
Takeda CEO-Elect Julie Kim Sets Two-Horizon Growth Plan on Back of Strong FY2025 Pipeline and Results
PremiumCompany Announcements
Takeda CEO-Elect Julie Kim Sets Two-Horizon Growth Plan on Back of Strong FY2025 Pipeline and Results
1M ago
6K
TAK
Takeda Details IFRS-Based Financial Notes and Group Restructuring in May 2026 Filing
PremiumCompany Announcements
Takeda Details IFRS-Based Financial Notes and Group Restructuring in May 2026 Filing
1M ago
6K
TAK
Takeda Sets June 24, 2026 Date for 150th Shareholders’ Meeting and Details Governance Agenda
PremiumCompany Announcements
Takeda Sets June 24, 2026 Date for 150th Shareholders’ Meeting and Details Governance Agenda
1M ago
6K
TAK
Takeda Expands Maribavir Into Pediatric CMV, Extending Long-Term Upside Potential
PremiumCompany Announcements
Takeda Expands Maribavir Into Pediatric CMV, Extending Long-Term Upside Potential
1M ago
TAK
Takeda Expands Real-World Data on OBIZUR, Supporting Its Rare Disease Strategy
PremiumCompany AnnouncementsTakeda Expands Real-World Data on OBIZUR, Supporting Its Rare Disease Strategy
1M ago
TAK
Takeda Earnings Call: Pipeline Strength Amid Profit Squeeze
Premium
Company Announcements
Takeda Earnings Call: Pipeline Strength Amid Profit Squeeze
1M ago
TAK
Jury finds Takeda caused about $885M in damages over generic delay, Reuters says
Premium
The Fly
Jury finds Takeda caused about $885M in damages over generic delay, Reuters says
2M ago
TAK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >